Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
SEC Accession No. 0000950170-25-093440
Filing Date
2025-07-02
Accepted
2025-07-02 19:55:37
Documents
1
Period of Report
2025-02-21

Document Format Files

Seq Description Document Type Size
1 4/A ownership.html 4/A  
1 4/A ownership.xml 4/A 4215
  Complete submission text file 0000950170-25-093440.txt   5966
Mailing Address C/O ARENA PHARMACEUTICALS, INC. 6154 NANCY RIDGE DRIVE SAN DIEGO CA 92121
Business Address C/O ARENA PHARMACEUTICALS, INC. 6154 NANCY RIDGE DRIVE SAN DIEGO CA 92121 (858) 453-7200
Aurentz Vincent (Reporting) CIK: 0001657494 (see all company filings)

Type: 4/A | Act: 34 | File No.: 001-39676 | Film No.: 251103409

Mailing Address 1000 N. WEST STREET, SUITE 1200 WILMINGTON DE 19801
Business Address 1000 N. WEST STREET, SUITE 1200 WILMINGTON DE 19801 (302) 295-3800
Inhibikase Therapeutics, Inc. (Issuer) CIK: 0001750149 (see all company filings)

EIN.: 263407249 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)